Newzen-138
Not Disclosed
Not DisclosedActive
Key Facts
About Newzen Pharma
NewzenPharma is a private, clinical-stage biotech founded in 2020, headquartered in San Diego, California, with additional offices in Princeton, New Jersey. The company is developing innovative cancer therapies centered on DNA repair inhibition, positioning itself in the competitive oncology space. While presenting an ambitious pipeline and an integrated R&D-to-manufacturing model, the company's early stage, unclear pipeline specifics, and potential inconsistencies in its public messaging present significant execution and credibility risks.
View full company profileTherapeutic Areas
Other Not Disclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| SAGE-689 | Sage Therapeutics | Phase 1 |
| SAGE-904 | Sage Therapeutics | Preclinical |
| BO-212 | Highlight Therapeutics | Research |
| Immunozen | Newzen Pharma | Not Disclosed |
| Newzen-40 | Newzen Pharma | Not Disclosed |
| AbbVie Partnership Program(s) | EvolveImmune Therapeutics | Pre-clinical |
| FYB209 | Formycon | Preclinical/Technical Development |
| FYB210 | Formycon | Preclinical/Technical Development |
| Undisclosed Target | Libra Therapeutics | Discovery |
| Eli Lilly Collaboration Program(s) | PepLib Biotech | Discovery/Pre-clinical |
| AstraZeneca Collaboration Program(s) | PepLib Biotech | Discovery/Pre-clinical |
| SRSD101 | Sirius Therapeutics | Phase 1 |